secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001437749-23-034076
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences expands board to 9 with three new directors
------------------------------------------------------------

- Appointed Dr. Claude Nicaise, Pierre Gravier, and Robert Anderson, Jr. effective Dec 6, 2023.
- Board expanded from 6 to 9 members; Anderson (Class I), Nicaise and Gravier (Class II).
- Nicaise led regulatory/clinical roles resulting in 14 drug approvals; Gravier is CFO of PTC Therapeutics.
- Anderson is former FBI Executive Assistant Director and cybersecurity expert.
- No committees assigned; none have material interests in reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/0001437749-23-034076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/sava20231208c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-034076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer